Black Rock Inc. Reneo Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Reneo Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 993,659 shares of RPHM stock, worth $1.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

993,659

Previous 983,304 1.05%

Holding current value

$1.65 Million

Previous $1.57 Million 4.83%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.59 - $1.74 $16,464 - $18,017	10,355 Added 1.05%	993,659 $1.65 Million
Q4 2023 Feb 13, 2024	BUY	$1.34 - $8.43 $488,408 - $3.07 Million	364,484 Added 58.9%	983,304 $1.57 Million
Q3 2023 Nov 13, 2023	BUY	$5.44 - $8.13 $880,708 - $1.32 Million	161,895 Added 35.43%	618,820 $4.72 Million
Q2 2023 Aug 11, 2023	BUY	$5.44 - $10.5 $2.36 Million - $4.55 Million	433,288 Added 1833.09%	456,925 $3 Million
Q1 2023 May 12, 2023	SELL	$2.44 - $6.42 $1,625 - $4,275	-666 Reduced 2.74%	23,637 $141,000

Q4 2022 Feb 13, 2023	BUY	$1.8 - $3.16 $900 - $1,580	500 Added 2.1%	24,303 $56,000
Q3 2022 Nov 14, 2022	BUY	$2.35 - $4.85 $1,858 - $3,836	791 Added 3.44%	23,803 $80,000
Q2 2022 Aug 12, 2022	SELL	$1.96 - $3.04 $576,269 - $893,805	-294,015 Reduced 92.74%	23,012 $61,000
Q1 2022 May 12, 2022	BUY	$2.94 - $9.07 $446 - $1,378	152 Added 0.05%	317,027 $932,000
Q4 2021 Feb 10, 2022	BUY	$6.07 - $9.68 $137,145 - $218,709	22,594 Added 7.68%	316,875 $2.71 Million
Q3 2021 Nov 09, 2021	BUY	$6.28 - $11.07 $27,989 - $49,338	4,457 Added 1.54%	294,281 $2.19 Million
Q2 2021 Aug 11, 2021	BUY	$7.78 - $15.0 $2.25 Million - $4.35 Million	289,824 New	289,824 $2.7 Million

Others Institutions Holding RPHM

# of Institutions

Shares Held

29.4M

Call Options Held

125K

Put Options Held

3.1K

View Full List

About Reneo Pharmaceuticals, Inc.

Ticker RPHM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,479,600
Market Cap $40.6M
Description
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...

More about RPHM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account